Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents
Based on favorable results from randomized clinical trials, oral posaconazole has been approved for ...
Invasive fungal infections are a potentially life-threatening complication in immunocompromised pati...
We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to...
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in ...
Posaconazole is the newest antifungal agent to be approved for use in Canada. With excellent in vitr...
Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activiti...
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz11Section of Infectious Diseases and Department...
Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and...
The invasive fungal infections are among the leading causes of morbidity, mortality and economic bur...
Background. Invasive fungal infections are found most frequently in immunosuppressed and critically ...
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
Background. Invasive aspergillosis is an important cause of morbidity and mortality in immunocomprom...
Invasive fungal infections are a major cause of morbidity and mortality among solid organ transplant...
International audiencePosaconazole is a triazole antifungal used to prevent invasive fungal infectio...
Based on favorable results from randomized clinical trials, oral posaconazole has been approved for ...
Invasive fungal infections are a potentially life-threatening complication in immunocompromised pati...
We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to...
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in ...
Posaconazole is the newest antifungal agent to be approved for use in Canada. With excellent in vitr...
Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activiti...
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz11Section of Infectious Diseases and Department...
Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and...
The invasive fungal infections are among the leading causes of morbidity, mortality and economic bur...
Background. Invasive fungal infections are found most frequently in immunosuppressed and critically ...
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive...
The new antifungal derivative posaconazole was tested against three clinical isolates of Cryptococcu...
Background. Invasive aspergillosis is an important cause of morbidity and mortality in immunocomprom...
Invasive fungal infections are a major cause of morbidity and mortality among solid organ transplant...
International audiencePosaconazole is a triazole antifungal used to prevent invasive fungal infectio...
Based on favorable results from randomized clinical trials, oral posaconazole has been approved for ...
Invasive fungal infections are a potentially life-threatening complication in immunocompromised pati...
We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to...